Bone Biologics Co. (OTC:BBLG – Get Free Report) fell 4.5% during mid-day trading on Wednesday . The company traded as low as $1.25 and last traded at $1.26. 21,851 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 1,505,719 shares. The stock had previously closed at $1.32.
Bone Biologics Stock Down 4.5 %
The business’s 50-day moving average price is $1.64 and its 200-day moving average price is $1.57. The firm has a market capitalization of $3.10 million, a PE ratio of -0.03 and a beta of 0.45.
About Bone Biologics
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Recommended Stories
- Five stocks we like better than Bone Biologics
- 5 Top Rated Dividend Stocks to Consider
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Williams-Sonoma Stock: Buy It and Never Let It Go
- Ride Out The Recession With These Dividend Kings
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.